3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Carboplatin
19
Paclitaxel
18
Fluorouracil
16
Cisplatin
16
pembrolizumab
15
Radiotherapy
14
Oxaliplatin
12
Irinotecan
12
Capecitabine
12
Cyclophosphamide
10
Radiation
8
Leucovorin
8
Docetaxel
8
fludarabine
6
Taxes
6
Gemcitabine
6
Trastuzumab
5
fludarabine phosphate
4
aldesleukin
4
LY6K protein, human
4
Fluorodeoxyglucose F18
4
Erlotinib Hydrochloride
4
Bevacizumab
4
spartalizumab
3
Surgical Procedures, Operative
3
S 1 (combination)
3
Pemetrexed
3
Nivolumab
3
Drug Therapy
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Esophageal Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled